News & Updates
Filter by Specialty:
SGLT2 inhibitors help prevent new-onset AF in diabetic Asians
Use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) may reduce the risk of new-onset atrial fibrillation (AF) relative to glucagon-like peptide-1 receptor agonists (GLP-1RAs) in Asian patients with type 2 diabetes mellitus (T2DM) in a real-world practice, reports a recent study.
SGLT2 inhibitors help prevent new-onset AF in diabetic Asians
18 Sep 2022
Poststroke statin treatment confers survival benefits for cancer patients
Statin treatment following ischaemic stroke appears to extend its benefits to improved survival in patients who also have had cancer, a study has found.
Poststroke statin treatment confers survival benefits for cancer patients
16 Sep 2022
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.
Adalimumab biosimilar performs well in chronic plaque psoriasis treatment
16 Sep 2022
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
16 Sep 2022
Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.